Thus, NEDD9 inactivation associates with higher in vivo aggressiveness in chronic myeloid leukemia (CML), since NEDD9 deficient p210Bcr/Abl transgenic mice show an increased number of granulocytes in peripheral blood, a hyperplasia of myeloid and megakaryocytic cells in the bone marrow, and a diffuse myeloid infiltration in the spleen, lung and liver, leading to earlier progression and shorter mouse survival, which support NEDD9 capacity to block CML progression [23]. The gene discussed is NEDD9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.